Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

PetIQ, Inc. PETQ NASDAQ

NASDAQ Global Select • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
42/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$31.00
+0.1%

PetIQ, Inc. (PETQ) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $30.98. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is PETQ = $31 (+0.1% upside).

Financials: revenue is $1.1B, +12.6%/yr average growth. Net income is $2M, growing at -4.2%/yr. Net profit margin is 0.2% (thin). Gross margin is 22.9% (+5.6 pp trend).

Balance sheet: total debt is $468M against $221M equity (Debt-to-Equity (D/E) ratio 2.12, leveraged). Current ratio is 2.27 (strong liquidity). Debt-to-assets is 53.9%. Total assets: $868M.

Analyst outlook: 5 / 6 analysts rate PETQ as buy (83%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 34/100 (Fail), Growth 48/100 (Partial), Past 25/100 (Fail), Health 33/100 (Fail), Moat 47/100 (Partial), Future 76/100 (Pass), Income 30/100 (Fail).

$31.00
▲ 0.06% Upside
Average Price Target
The 12-month price target for PetIQ, Inc. is $31.00.

PETQ SharesGrow Score Overview

42/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 34/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 47/100
Gross margin is + market cap
FUTURE 76/100
Analyst outlook — as buy
INCOME 30/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PETQ

✗
VALUE Fail
34/100
PETQ trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $31, implying +0.1% from the current price $31. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
PETQ: +12.6%/yr revenue is, -4.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
PETQ: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✗
HEALTH Fail
33/100
Balance sheet PETQ: Debt-to-Equity (D/E) ratio 2.12 (leveraged), Current ratio is 2.27 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
47/100
PETQ: Gross margin is 22.9% (+5.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 47/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
76/100
Analyst outlook: 5 / 6 analysts rate PETQ as buy (83%). Analyst consensus target is $31 (+0.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
30/100
PETQ: Net profit margin is 0.2%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range15.09-31.06
Volume928.27K
Avg Volume (30D)884.43K
Market Cap$919.17M
Beta (1Y)1.74
Share Statistics
EPS (TTM)0.07
Shares Outstanding$29.14M
IPO Date2017-07-21
Employees1,121
CEOMcCord Christensen
Financial Highlights & Ratios
Revenue (TTM)$1.1B
Gross Profit$252.74M
EBITDA$81.49M
Net Income$2.13M
Operating Income$60.02M
Total Cash$116.37M
Total Debt$468.3M
Net Debt$351.93M
Total Assets$868.23M
Price / Earnings (P/E)423.8
Price / Sales (P/S)0.83
Analyst Forecast
1Y Price Target$31.00
Target High$31.00
Target Low$31.00
Upside+0.1%
Rating ConsensusBuy
Analysts Covering6
Buy 83% Hold 17% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS71639T1060

Price Chart

Track all markets on TradingView
PETQ
PetIQ, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Drug Manufacturers - Specialty & Generic
15.09 52WK RANGE 31.06

People Also View

ZTS
ZTS
Zoetis Inc.
$120.76
-0.29%
 RGC
RGC
Regencell Bioscience Holdings Limited
$29.81
-1.00%
 NBIX
NBIX
Neurocrine Biosciences, Inc.
$131.44
+0.48%
 RDY
RDY
Dr. Reddy's Laboratories Limited
$12.94
-1.45%
 SUPN
SUPN
Supernus Pharmaceuticals, Inc.
$49.94
-0.34%
 PBH
PBH
Prestige Consumer Healthcare Inc.
$57.57
+1.61%
 PAHC
PAHC
Phibro Animal Health Corporation
$55.01
-6.79%
 DCPH
DCPH
Deciphera Pharmaceuticals, Inc.
$25.59
+0.08%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message